Naval gazing the sp is simply not healthy in a market where retail coin will be pulled from equities for the next 6 months
watch the pain the ETFs will experience in the coming months - there is far more retail exposure through these instruments than many understand and a vast majority will crash and burn by 4th qtr 2023....they only exist to leverage retail -
THAT is what is hurting IHL - speculation that it is a decision by the BoD to take an easy 13mil - specifically to lay some sort of blame at JLs' door is also nonsense
There is no bottom ! the SP can go lower - it can go higher - or it can stagnate
supply and demand is the only driver of an sp
It is not a company reflection of the value drivers in the IHL locker - its that simple
all the emotional crap thrown around here should simply be ignored ....the i told you so brigade only demonstrate that they really have no grasp
of supply and demand driversand why it occurs
https://www.wsj.com/articles/collecting-pharmas-scraps-can-pay-off-for-this-biotech-40a95249?mod=Searchresults_pos2&page=1'So why would Pfizer divest what appears to be a promising drug? The answer, like much of what Pfizer and other big pharma companies are doing these days, has to do with the patent cliff. Pfizer will see about $17 billion of annual revenue from blockbusters such as blood thinner Eliquis go away later this decade due to expected patent losses. To build a new product line, Pfizer needs to spend more on research and development as well as marketing. That means it has to let some things go, especially if those assets won’t be delivering a return on investment any time soon. And when it comes to irritable-bowel disease, the company has an even more promising asset: an oral pill for ulcerative colitis that it got from a recent $6.7 billion bet on Arena Pharmaceuticals.
Irritable bowel disease is an inflammatory disease - what are IHL developing?
yeah - a multi use anti inflammatory 675A
A Pfizer spokeswoman wrote in an email that the company is actively “pursuing new, creative ways of working with other parties that will complement and enhance our internal R&D efforts and add capacity and flexibility to support our growing clinical portfolio.” Mr. Gline said in an interview that Pfizer couldn’t develop this “phenomenal drug for complicated internal reasons.” And what they want, he added, “is a partner who can give them upside with execution capability.”
understanding the company and the pipeline products and value drivers these guys are putting place is what very few are focusing so they will be surprised when the BP offersa and transactions start - out the end of the phase III trials when the dollars are being offered = it really is that simple and not related to the sp in any way
https://www.wsj.com/articles/collecting-pharmas-scraps-can-pay-off-for-this-biotech-40a95249?mod=Searchresults_pos2&page=1glah